de Feria Cardet RE, Hofman MS, Segard T, et al. - This study was undertaken to ascertain the cost-effectiveness of prostate-specific membrane antigen (PSMA)-PET/CT vs conventional imaging. Researchers constructed a cost-effectiveness analysis applying data from the proPSMA study. proPSMA included patients with high-risk prostate cancer assigned to conventional imaging or ⁶⁸Ga-PSMA-11 PET/CT with planned health economics data collected. From an Australian societal perspective, the cost-effectiveness analysis was performed. The data exhibited that, in comparison with conventional imaging, PSMA PET/CT has lower direct comparative costs and is more accurate for initial staging of men with high-risk prostate cancer. In addition, this gives a compelling evidence for adopting PSMA PET/CT into clinical practice.